Nalaganje...
Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
INTRODUCTION: The mineralocorticoid receptor (MR) blocker esaxerenone is a new treatment for hypertension in Japan and under development for treatment of diabetic nephropathy. Hepatic impairment is known to impact the pharmacokinetics (PKs) of other MR blocking drugs. The aim of the present study wa...
Shranjeno v:
| izdano v: | Adv Ther |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Healthcare
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6979450/ https://ncbi.nlm.nih.gov/pubmed/31705436 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-01121-2 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|